News
A couple of artificial intelligence platforms in ophthalmology have taken significant steps forward in the past few weeks, one on this side of the Atlantic,…
Read More
By Larry Haimovitch and Richard Mark Kirkner Someday for some company, the business of selling corneal inlays to treat presbyopia could be very lucrative, but…
Read More
In January, the OIS Index scratched out a small gain, but underperformed its relevant benchmarks. The OIS Index gained 0.3%, compared with gains of 7%…
Read More
Clinical Trial Updates Due at Angiogenesis Meeting Investigators will present a host of updates on clinical trials in retina at Angiogenesis, Exudation and Degeneration 2018…
Read More
Regeneron Pharmaceuticals‘ stock took a double hit in January upon news that two companies are making progress on biosimilars of Eylea (aflibercept) treatment for age-related…
Read More
At the 36th annual JP Morgan Healthcare Conference in San Francisco, Allergan CEO Brent Saunders said a disconnect exists between the company’s 2017 results and…
Read More
Aerie Pharmaceuticals’ CEO and chairman Vicente Anido Jr., PhD, says the company got “an early Christmas present” when the Food and Drug Administration approved Rhopressa…
Read More
As the first drug company to get Food and Drug Administration Approval for a gene therapy to treat an inherited disease, Spark Therapeutics has also…
Read More
December was a month of positive milestones for key companies in the OIS Index. On December 18, more than two months before its February 28…
Read More
pSivida Set to File 3-year Durasert NDA pSivida Corp. this month expects to file a New Drug Application with the Food and Drug Administration for…
Read More
As House and Senate negotiators reportedly reached agreement on a tax-reform package, the fate of the orphan drug tax credit remained uncertain. Advocates have been…
Read More
Instead of looking at the year past, OIS Weekly is wrapping up 2017 by looking at the year ahead. Here’s a rundown of significant regulatory…
Read More
SUBSCRIBE TO OIS NEWS
Get Our Weekly Newsletter About The Latest In Ophthalmic Innovation.
We respect your privacy and promise to never send you spam.
![OIS-ANTERIOR-NEW-DATE-750x420[4300]](https://ois.net/wp-content/uploads/2020/03/OIS-ANTERIOR-NEW-DATE-750x4204300.jpg "OIS-ANTERIOR-NEW-DATE-750x420[4300]")